Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
REDWOOD CITY, Calif.--(BUSINESS WIRE)--ApniCure, Inc., a medical device company focused on developing and commercializing novel home-use devices for the treatment of obstructive sleep apnea (OSA), announced the publication of positive results from the ATLAST clinical trial of its Winx® Sleep Therapy System, a first-of-its kind, lifestyle-friendly treatment for mild, moderate and severe OSA. The Winx system has an innovative design to increase treatment adherence and overall efficacy without the inconvenience of a mask. The study results showed significant improvements in both apnea-hyponea index (AHI), a common measurement of sleep apnea severity, and oxygen desaturation index (ODI) on the first night of treatment and following 28 days of Winx usage. The study also demonstrated high levels of patient adherence with Winx, as well as significant improvements in sleep architecture and subjective sleepiness. The results are published in Sleep Medicine.
Help employers find you! Check out all the jobs and post your resume.
